F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function

R S Beanlands; R A deKemp; S Smith; H Johansen; T D Ruddy

doi:10.1016/s0002-9149(97)00054-4

F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function

Am J Cardiol. 1997 Apr 15;79(8):1092-5. doi: 10.1016/s0002-9149(97)00054-4.

Authors

R S Beanlands¹, R A deKemp, S Smith, H Johansen, T D Ruddy

Affiliation

¹ Cardiac PET Centre, University of Ottawa Heart Institute, Ontario, Canada.

PMID: 9114769
DOI: 10.1016/s0002-9149(97)00054-4

Abstract

The effect of F-18-fluorodeoxyglucose positron emission tomography imaging on decision making in the selection of patients with impaired ventricular function for revascularization was determined in 87 patients. In 57% of patients, positron emission tomography data influenced management decisions, indicating an important effect of myocardial viability determination on difficult therapy decisions in these patients.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Coronary Disease / complications
Coronary Disease / diagnostic imaging
Coronary Disease / metabolism
Coronary Disease / surgery*
Decision Making*
Deoxyglucose / analogs & derivatives*
Female
Fluorine Radioisotopes*
Fluorodeoxyglucose F18
Humans
Male
Middle Aged
Myocardial Revascularization
Myocardium / metabolism*
Prospective Studies
Tomography, Emission-Computed* / methods
Ventricular Dysfunction, Left / diagnostic imaging*
Ventricular Dysfunction, Left / etiology
Ventricular Dysfunction, Left / metabolism
Ventricular Dysfunction, Left / surgery

Substances

Fluorine Radioisotopes
Fluorodeoxyglucose F18
Deoxyglucose